Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have dramatically changed the prognosis of patients with chronic myeloid leukemia (CML). They have a distinct toxicity profile that includes glycometabolic alterations: i.e. diabetes mellitus (DM), impaired fasting glucose (IFG), and the metabolic syndro...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Iurlo, Alessandra, Orsi, Emanuela, Cattaneo, Daniele, Resi, Veronica, Bucelli, Cristina, Orofino, Nicola, Sciumè, Mariarita, Elena, Chiara, Grancini, Valeria, Consonni, Dario, Orlandi, Ester Maria, Cortelezzi, Agostino
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Clinical Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741815/
https://ncbi.nlm.nih.gov/pubmed/26376678
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki